2023 Cancer Steering Committee Scientific Symposium

Day 1: Tuesday November 14, 2023

11:00  Registration & Lunch

12:00  Opening Remarks

12:45  Session 1: Independent vs. Synergistic Activity of Drugs in Combination

Moderator: Emmett Schmidt, Merck and Co; Inc

12:45  Keynote: Drug Independence: Implications for Drug Discovery and Precision Medicine in Oncology
Peter Sorger, Harvard Medical School

1:20  Debate: Independent Action vs. Synergy
Adam Palmer, UNC Chapel Hill
Michael A. Curran, The University of Texas MD Anderson Cancer Center / ImmunoGenesis Inc.

2:00  Panel Discussion: When will precision medicine replace the “bet hedging” used in current combination cancer therapies?
Geoff Oxnard, Loxo Oncology @ Lilly
Emmett Schmidt, Merck and Co; Inc
David Solit, Memorial Sloan Kettering Cancer Center
Baolin Zhang, U.S. Food & Drug Administration

2:45  Coffee Break

3:15  Keynote: Novel Endpoint Development in Oncology
Nicole Gormley, U.S. Food & Drug Administration

3:50  Working Session 1: Digital and Computational Pathology
Moderator: Brandon Gallas, U.S. Food & Drug Administration

3:50  Digital and Computational Pathology Past, Present and Future
J. Carl Barrett, University of North Carolina

4:05  Introduction to the Pathology Innovation Collaborative Community (PICC): Challenges and Needs in Digital Pathology
Joe Lennerz, MGH

4:15  MedPerf: An open benchmarking platform for medical AI, enabling healthcare stakeholders to assess the performance of AI models in an efficient and human-supervised approach
Alex Karargyris, MLCommons

4:30  Collecting, curating, and sharing regulatory-ready data to assess the performance of pathologists and AI/ML models
Brandon Gallas, U.S. Food & Drug Administration
4:45  Coffee Break
5:00  Bridge of Trust – From Patient Care to Innovation
     Matthew O. Leavitt, LUMEA & DDx Foundation
5:15  A Multi-Stakeholder Regulatory Science Initiative to Create a Sustainable Ecosystem for Data
     Driven Diagnostics
     Joe Lennerz, MGH
5:30  Interactive Data Gathering: Attendee Polls
5:45  Panel Discussion
     Moderator: Joe Lennerz, MGH
     Kim RM Blenman, Yale University
     Brandon Gallas, U.S. Food & Drug Administration
     Alexandra N. Kalof, University of Vermont Health Network
     Laura Lasiter, AstraZeneca
     J. Carl Barrett, University of North Carolina
     Alex Karargyris, MLCommons
     Matthew O. Leavitt, LUMEA & DDx Foundation
6:15  Reception
Day 2: Wednesday November 15, 2023

8:00  Registration & Breakfast

9:00  Opening Remarks

9:15  Session 2: Early Disease – Detection and Treatment
     Moderator: Gary Kelloff, National Cancer Institute, NIH
     9:15  Keynote: Rare Cancer Models for Developmental Therapeutics
           James H. Doroshow, National Cancer Institute, NIH
     9:50  Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease
           Bruce E. Johnson, Dana-Farber Cancer Institute

10:15  Coffee Break

10:30  Panel Discussion
       Nicholas C. Dracopoli, Delfi Diagnostics
       Robert Iannone, Jazz Pharmaceuticals
       Jennifer Litton, The University of Texas MD Anderson Cancer Center
       Elad Sharon, Dana-Farber Cancer Institute

11:30  CSC Project Highlight: The Promise of Early Detection and Interception in Myeloma
       Irene Ghobrial, Dana-Farber Cancer Institute

12:00  Lunch

1:00  Working Session 2: Liquid Biopsy – from Mutations to Gene Expression
     Moderator: Mickey Williams, Frederick National Laboratory for Cancer Research
     1:00  Keynote: ctDNA analysis as a tool for precision drug development
           Geoff Oxnard, Loxo Oncology @ Lilly

     Liquid Biopsy Today
     1:35  Liquid Biopsies for Solid Tumor Drug Development: Regulatory Considerations
           Paz Vellanki, U.S. Food & Drug Administration
     1:55  Development of FNIH Quality Control Materials for Circulating Tumor DNA
           Chris Karlovich, Frederick National Laboratory for Cancer Research

     Liquid Biopsy Tomorrow
     2:15  MRD in AML
           Christopher Hourigan, Intramural Program, NHLBI, NIH
     2:35  Exploring the potential of epigenomic liquid biopsies to impact cancer care
           Jacob Berchuck, Dana-Farber Cancer Institute, Harvard Medical School
2:55 From Clinical Outcome to Clinical Assay: A Study of Blood-Based, 3D Genomic Biomarkers for the Checkpoint Inhibitor Response Test (CiRT)
Alexandre Akoulitchev, Oxford BioDynamics

3:15 Panel Discussion: Objectives for CSC Liquid Biopsy Project in Development
Alexandre Akoulitchev, Oxford BioDynamics
Jacob Berchuck, Dana-Farber Cancer Institute, Harvard Medical School
Craig Cummings, Genentech
Zhiyong He, NIST
Christopher Hourigan, NHLBI
Chris Karlovich, Frederick National Laboratory for Cancer Research
Diana Merino Vega, AstraZeneca
Paz Vellanki, U.S. Food & Drug Administration

4:10 Break-out Groups: How can the CSC translate development of liquid biopsy technologies into an impactful public-private partnership

5:15 Closing Remarks